RAS/BRAF wild-type metastatic high-methylated colorectal cancer has gene expression patterns related to MSI-H and BRAF V600E mutant: a translational research

Metastatic colorectal cancer (mCRC) differs clinically based on RAS and BRAF mutations or DNA methylation. However, in mCRC, the prognostic value and biological characteristics of genome-wide DNA methylation status (GWMS) in each RAS/BRAF genotype is unknown. To clarify this, primary tumor samples from patients with informed consent in the phase III TRICOLORE study were collected, and RAS and BRAF mutations, immunohistochemical staining of mismatch repair-related proteins, comprehensive gene expression, and genome-wide DNA methylation were analyzed. The tumor samples were classified into high-methylated colorectal cancer (HMCC) and low-methylated colorectal cancer (LMCC). Gene set enrichment analysis (GSEA) was conducted using microarray data. A total of 226 patients were included and classified into the RAS/BRAF wild-type (wt) (n = 125), RAS mutant (mt) (n = 87), and BRAF mt (n = 14), of whom 22 (17.6%), 30 (34.5%), and 14 (100%) had HMCC. HMCC exhibited significantly worse overall survival (OS) than that of LMCC in the RAS/BRAF wt group but not in the RAS mt group. In GSEA, RAS/BRAF wt HMCC was associated with microsatellite instability and BRAF V600E mutation. The poor prognosis of RAS/BRAF wt HMCC may be attributed to gene expression patterns associated with microsatellite instability and BRAF V600E mutation.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-03-08
DOI
https://doi.org/10.1038/s41598-026-42033-w
Primary Topic
Colorectal Cancer Treatments and Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

RAS/BRAF wild-type metastatic high-methylated colorectal cancer has gene expression patterns related to MSI-H and BRAF V600E mutant: a translational research

T. Yamaguchi, Hisatsugu Ohori, Keigo Komine, Masato Nakamura et al.
Scientific Reports
Colorectal Cancer Treatments and Studies
article

RAS/BRAF wild-type metastatic high-methylated colorectal cancer has gene expression patterns related to MSI-H and BRAF V600E mutant: a translational research

T. Yamaguchi, Hisatsugu Ohori, Keigo Komine, Masato Nakamura, Shonosuke Wakayama, S. Morita, Yasuhide Yamada, Masanori Kotake, Atsushi Satō, Hideo Baba, Yasuhiro Sakamoto, Hitoshi Kondo, Yoshimitsu Kobayashi, Akira Okita, K Ouchi, K. Amagai, A. Takashima, Shin Takahashi, Ken Shimada, Mika Watanabe, Chikashi Ishioka, Satoshi Yuki, Yoshito Komatsu, Tadamichi Denda
article en

Abstract

Metastatic colorectal cancer (mCRC) differs clinically based on RAS and BRAF mutations or DNA methylation. However, in mCRC, the prognostic value and biological characteristics of genome-wide DNA methylation status (GWMS) in each RAS/BRAF genotype is unknown. To clarify this, primary tumor samples from patients with informed consent in the phase III TRICOLORE study were collected, and RAS and BRAF mutations, immunohistochemical staining of mismatch repair-related proteins, comprehensive gene expression, and genome-wide DNA methylation were analyzed. The tumor samples were classified into high-methylated colorectal cancer (HMCC) and low-methylated colorectal cancer (LMCC). Gene set enrichment analysis (GSEA) was conducted using microarray data. A total of 226 patients were included and classified into the RAS/BRAF wild-type (wt) (n = 125), RAS mutant (mt) (n = 87), and BRAF mt (n = 14), of whom 22 (17.6%), 30 (34.5%), and 14 (100%) had HMCC. HMCC exhibited significantly worse overall survival (OS) than that of LMCC in the RAS/BRAF wt group but not in the RAS mt group. In GSEA, RAS/BRAF wt HMCC was associated with microsatellite instability and BRAF V600E mutation. The poor prognosis of RAS/BRAF wt HMCC may be attributed to gene expression patterns associated with microsatellite instability and BRAF V600E mutation.

Scientific Reports
SHOWA Medical University (JP), Hirosaki University (JP), Tohoku University (JP), Kyoto University (JP), NTT Medical Center (JP), Tokyo Metropolitan Komagome Hospital (JP), Tohoku University Hospital (JP), National Center for Global Health and Medicine (JP), Tonan Hospital (JP), Osaki Citizen Hospital (JP), Chiba Cancer Center (JP), Kaketsuken (Japan) (JP), Tohoku Medical and Pharmaceutical University Hospital (JP), Ibaraki Prefectural Central Hospital (JP), Hokkaido University Hospital (JP), National Cancer Center Hospital East (JP), Aizawa Hospital (JP), Kouseiren Takaoka Hospital (JP), SHOWA Medical University Koto Toyosu Hospital (JP)
Taiho Pharmaceutical, Tokyo Cooperative Oncology Group, Japan Society for the Promotion of Science
No poverty
Openalex Percentile: Top 29%
Colorectal Cancer Treatments and Studies
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.